ArticleFrontiers in cardiovascular medicine2025
Correlation between α-ketoglutarate and the oxidative stress response in patients with coronary heart disease and prognostic analysis of interventional therapy for coronary heart disease.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To explore the correlation between α-ketoglutarate and the oxidative stress response in patients with coronary heart disease (CHD) and to analyze the prognosis of CHD patients receiving interventional treatment. Methods: A total of 318 CHD patients admitted from September 2020 to September 2023 were selected and divided into a conservative medical treatment group (159 patients) and an interventional treatment group (159 patients) according to the treatment plan. The interventional treatment group was divided into an event group and a nonevent group according to whether the primary endpoint event occurred; another 59 patients with healthy physical examination results during the same period composed the control group. The results: The serum TAC, SOD, CAT, and GSH levels in the conservative medical treatment group were lower than those in the control group ( Conclusion: α-Ketoglutarate is related to oxidative stress in patients with CHD. The lower the serum α-ketoglutarate level is, the greater the likelihood that adverse events will occur.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.